J&J cuts MFN deal with the Trump administration, bolsters US onshoring efforts [Yahoo! Finance]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Yahoo! Finance
Through a voluntary agreement with the Trump administration, J&J will now offer unspecified medicines from its portfolio at lower prices to cash-paying patients through the government-run, direct-to-consumer (DTC) platform, TrumpRx.gov. In exchange for slashing its rates on medicines, the New Jersey pharma will gain immunity to the 100% tariffs on imported branded pharmaceuticals threatened by Trump back in April 2025. J&J's deal comes amid a swathe of agreements between pharma companies and the Trump administration, with nine deals involving Genentech, Gilead Sciences, GSK, MSD, Amgen, Bristol Myers Squibb (BMS), Boehringer Ingelheim, Novartis and Sanofi announced in December 2025. Pfizer and AstraZeneca were the first to come to a drug pricing agreement with the White House, with both companies striking deals in October 2025. These agreements were set in stone after Trump called on 17 large pharma companies to cut drug prices on the US market. Of these 17, AbbVie and Regene
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Gilead Sciences (NASDAQ:GILD) had its price target lowered by analysts at Morgan Stanley from $151.00 to $150.00. They now have an "overweight" rating on the stock.MarketBeat
- Gilead Sciences (NASDAQ:GILD) had its "outperform" rating reaffirmed by analysts at BMO Capital Markets.MarketBeat
- Gilead Sciences: From All-Time Highs To Higher Highs [Seeking Alpha]Seeking Alpha
- UBS and Citi Go Bullish on Gilead Sciences (GILD) [Yahoo! Finance]Yahoo! Finance
- The Bull Case For Gilead Sciences (GILD) Could Change Following New OncoNano Drug-Delivery Collaboration [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 10/30/25 - Beat
GILD
Sec Filings
- 1/5/26 - Form 4
- 12/30/25 - Form 4
- 12/29/25 - Form 144
- GILD's page on the SEC website